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Perils of Ancestry-Based 
Drug Prescribing
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The term “personalized medicine” in-
creasingly has come to mean the use 
of genetic testing in prescribing phar-
maceutical products.1 The scientific 
basis of this approach to medicine is 
that, because of genetic variations, 
humans differ in their response to 
treatments. This observation is the 
cornerstone of pharmacogenetics and 
pharmacogenomics.  
Ethical problems sometimes arise 
when this principle is applied on a 
group basis. For example, if humans 
could be divided into two genetic 
groups, a group with genotype A and 
a group with genotype B, members of 
each group might respond differently 
to a particular drug.  The group with 
genotype A might have an adverse 
reaction to a drug.  The group with 
genotype B might have a therapeutic 
response to the drug.  Personalized 
medicine focuses on ensuring that in-
dividuals likely to respond positively 
to a drug receive it, and individuals 
likely to respond negatively are not 
given the drug. Although often de-
fined as a way of individually tailor-
ing treatments, personalized medi-
cine is better characterized as a way 
of tailoring treatments to groups of 
people with some shared genetic trait 
or traits. Hence, personalized medi-
cine may be viewed as “subgroup 
medicine.”
A key question of subgroup medi-
cine is to ask how should human sub-
groups be defined.  The method of 
defining subgroups determines who 
is most likely to be tested for a genetic 
trait and therefore who receives or 
does not receive certain treatments. 
For example, if subgroups are defined 
based on height, a scientist might de-
termine that people over six feet tall 
are more likely to have a certain al-
lele, and that this allele determines 
the response to a drug for a particular 
disorder. Thus, people over six feet 
tall would be more likely to receive a 
genetic test, and clinicians would use 
the test result to determine whether 
they should receive a particular drug. 
The result would be an increase in the 
“personalized”care for people over six 
feet tall. On the other hand, people 
under six feet tall with the same dis-
ease would not receive the genetic test 
and the opportunity for personalized 
medicine.  
In a world of unlimited resources, 
everyone who needed a drug with 
pharmacogenetic information associ-
ated with it would receive the appro-
priate genetic test prior to being pre-
scribed this drug.  However, genetic 
testing of all people who might ben-
efit from a drug raises cost concerns. 
In addition, recognition of pheno-
typic homogeneity (such as similar 
blood pressure measurements) often 
precedes scientific identification of 
the genetic basis of disease. Conse-
quently, researchers often attempt to 
determine which subgroups of people 
are most likely to have certain known 
or presumed alleles. In the absence 
of genotypic information, subgroups 
may be defined based on a person’s 
physical or social environment, dis-
ease type, symptoms, and so on.  The 
focus of this article is the use of ances-
try for defining subgroups.  Recently, 
ancestry has been used to identify 
a subgroup of people most likely to 
have a certain allele linked to an ad-
verse drug response, and the FDA’s 
policy response to this scientific in-
formation raises serious concerns.
Overview of Unique 
Carbamazepine Labeling
On December 12, 2007, an FDA Alert 
was issued that modified the drug 
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labeling for the anti-seizure medi-
cation carbamazepine by including 
genotype and ancestry as factors to 
consider when prescribing the drug.2 
The alert stated that potentially fatal 
skin reactions, Stevens Johnson Syn-
drome and Toxic Epidermal Necro-
lysis (SJS/TEN), can be caused by 
carbamazepine therapy.  SJS/TEN 
results in blisters that can be perma-
nently disabling or lethal.  The FDA 
Alert indicates that patients with 
the genetic marker HLA-B*1502 are 
more likely to have this reaction when 
taking carbamazepine.3   If the label 
simply made these statements, phy-
sicians prescribing carbamazepine 
would have to question whether an 
individual had this particular allele 
before prescribing the drug.  This new 
information might lead physicians to 
order genetic testing for all patients 
prior to prescribing carbamazepine. 
Alternatively, they might decide to 
choose a different drug with similar 
therapeutic properties as carbamaze-
pine without the need for genetic test-
ing.  However, the FDA Alert does not 
end with these statements.  Instead, 
another layer of complexity is added 
to the algorithm used for prescribing 
carbamazepine.  
The FDA Alert indicates that the 
genetic variant HLA-B*1502 occurs 
“almost exclusively” in patients with 
ancestry across “broad areas of Asia, 
including South Asian Indians.”4  This 
statement is based on a number of 
studies performed in patients labeled 
as Caucasian, French, German, eth-
nic Han Chinese residing in Taiwan 
or Hong Kong, and Chinese descen-
dants.5  The studies also include three 
patients born in Vietnam, Cambodia, 
and Reunion Island, respectively, who 
were thought to have Asian ancestry. 
The FDA Alert also indicates that 10-
15% of people from China, Thailand, 
Malaysia, Indonesia, the Phillipines, 
and Taiwan carry this gene variant, 
but no supporting research studies 
are provided.6  Also, the FDA Alert 
indicates that about 2–4% of South 
Asians and less than 1% of people in 
Japan in Korea have this allele, but no 
supporting research studies are pro-
vided for these statements either.7  
The referenced studies used differ-
ent approaches to determine ances-
try (also labeled as “ethnicity” in one 
study) including: skin color, place of 
birth, and place of birth of the per-
son’s parents.  In two of the studies, 
no clear method of determining an-
cestry was discussed.  Contrary to the 
FDA Alert, these individuals were not 
from broad areas of Asia, but instead, 
a select group of Asian countries.  In 
some cases, only one individual repre-
sented the population of the country, 
which is clearly insufficient to draw a 
conclusion about the frequency of the 
allele in that population.  Further, the 
FDA Alert is not specific about the 
definition of Asia.  In fact, a modern 
map of Asia includes a much larger 
region than these studies cover.8  A 
number of countries are not included 
in these studies, such as Russia, which 
makes up nearly half of Asia, Mongo-
lia, Turkey, Saudi Arabia, and more. 
Hence, the statement that people 
from broad areas of Asia have this al-
lele seems to lack support.
The FDA Alert also indicates that 
the allele is “largely absent in individ-
uals not of Asian origin.”  However, 
no studies are provided which assess 
the prevalence of this allele in other 
populations, except individuals la-
beled as Caucasian, French, and Ger-
man.  For example, no African popu-
lation studies are referenced.  A more 
thoughtful alert would have recog-
nized the limitations of these studies 
and stated that the prevalence of the 
allele in other populations of various 
ancestral backgrounds has yet to be 
determined.
The FDA Alert also states that 
patients with ancestry from areas in 
which the allele is present (presum-
ably “broad areas of Asia”) should 
be screened before starting treat-
ment.  With these statements the 
FDA creates a new standard of care 
for physicians.  Given this informa-
tion, a physician must decide first if 
a patient needs carbamazepine, then 
determine if the patient is of Asian 
ancestry in calculating the risk of an 
adverse reaction and the need for a 
genetic test.  It is unclear how the 
physician is to determine whether a 
patient has ancestry from broad areas 
of Asia.  This problem arises when-
ever ancestry or other social catego-
ries are used in stratifying patients for 
subgroup medicine.  
To date, biomedical researchers 
and physicians do not have a widely 
used test to determine if a person is of 
Asian ancestry or has ancestry from 
any other region.  As a result, both re-
searchers and physicians can only ask 
a patient and hope that the patient 
is right. With an increasingly mobile 
and admixed population, patients’ 
assumptions about their ancestry 
might not always be correct. The 
FDA’s new approach to drug labeling 
thus increases the responsibilities of 
patients, and with potentially serious 
consequences. 
The FDA Alert further states that if 
an individual tests positive for the al-
lele that he or she should not receive 
carbamazepine unless the “benefit 
clearly outweighs the risk of serious 
skin reactions.”9  The FDA provides no 
guidance on how to weigh these risks 
and benefits.  In addition, the alert 
states that patients who have taken 
carbamazepine for a few months 
without having skin reactions are at 
low risk of these events taking place. 
Ninety percent of people are thought 
to react within the first few months, 
with 10% having reactions at a later 
point.10  The alert states that this low 
risk exists even for individuals who 
Recently, ancestry has been used to identify a 
subgroup of people most likely to have a certain 
allele linked to an adverse drug response, and the 
FDA’s policy response to this scientific information 
raises serious concerns.
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are positive for the genetic marker 
and for patients of all ethnicities or 
genotypes, thereby contradicting, 
to some degree, the focus on people 
of Asian ancestry.  The alert also 
states that SJS/TEN can occur even 
in people outside of the high-risk 
groups, so physicians should watch 
for symptoms regardless of whether 
a patient has the HLA-B*1502 allele. 
This statement seems to acknowledge 
the confusion caused by the focus on 
ancestry and provides a way for the 
FDA to recognize that risks exist for 
anyone taking the drug.  Finally, the 
alert indicates that all of this informa-
tion will be included in updated drug 
labeling for carbamazepine. Overall, 
the alert provides unacceptably vague 
and confusing guidance for physi-
cians seeking to utilize this informa-
tion to improve patient care and in-
forming patients.
Cost Concerns
Because of the focus on people of 
Asian ancestry, the cost of care may 
increase for one subgroup of indi-
viduals but not others.  Depending on 
the cost of genetic testing, individuals 
who are believed to have Asian ances-
try will pay more to receive carbam-
azepine than individuals who do not 
think they have Asian ancestry.  This 
increased cost for a particular group 
may lead to a number of problems. 
The test may be viewed as a method 
of making these patients pay more for 
their care, and thereby discriminating 
against the group.  Such cost concerns 
could lead to disparities in who re-
ceives this drug – with people of Asian 
ancestry less likely to receive the drug 
in order to avoid the costs.  These cost 
concerns may seem more daunting 
depending on whether insurers ap-
prove payment for the genetic test. 
In particular, individuals who receive 
government-financed health care, in-
cluding Medicaid and Medicare, are 
likely to have greater cost concerns 
when considering genetic testing for 
which there is usually no reimburse-
ment.  Also, the question could arise 
as to whether these public programs 
would be engaging in race or national 
origin discrimination if they do not 
pay for genetic testing. Similarly, if 
private insurers do not pay for this 
test, they could be viewed as also dis-
criminating against a socially defined 
group of individuals.  
On the other hand, payers might 
conclude that it is cost-effective to 
pay for genetic testing for people who 
are at high risk in order to save money 
that would be spent treating patients 
with SJS/TEN.  The availability of 
this test, especially for patients re-
ceiving public insurance, would likely 
be based on whether the prevention 
of harm cost less than dealing with 
the harm of SJS/TEN. Because SJS/
TEN can be fatal, the benefits of pre-
vention may be greater for those indi-
viduals most at risk.  Thus, insurance 
companies would need to decide if ge-
netic testing should be approved only 
for certain subgroups, because of the 
FDA labeling, or if testing should be 
approved for all people who need car-
bamazepine.  These problems spring 
from the lack of a clear indication of 
the role of ancestry in allele frequency 
and the lack of a method of determin-
ing ancestry.  Hence, a more scientific 
approach of classifying people with 
particular ancestral backgrounds 
would be useful for public and private 
insurers.
Conclusion
The FDA’s use of ancestry in label-
ing carbamazepine is analogous to 
the FDA’s racially limited approval of 
the drug BiDil, which was labeled as 
being for African Americans only.11 
The BiDil approval turned out to be 
scientifically, ethically, and commer-
cially problematic.12  BiDil and car-
bamazepine demonstrate the need 
for a better approach than stratify-
ing people based on self-identified 
or “researcher identified” ethnicity or 
ancestry.  
The use of ancestry to stratify pop-
ulations is appealing because it is eas-
ier and less costly than genotyping. 
Yet, such an approach requires two 
key factors: (1) a scientifically valid 
way of ascertaining ancestry, and (2) 
there must be definitive evidence of 
an association between a particular 
genotype and a certain ancestry.  Over 
time, low-cost genetic testing will ob-
viate the need to use ancestry as a 
low-cost surrogate for genotype.  In 
the interim, scientifically defensible 
methods and definitions of ancestry 
need to be developed.
The inclusion of genetic informa-
tion in the drug labeling of carba-
mazepine holds promise for individu-
als who have the HLA-B*1502 allele, 
which is linked to adverse reactions 
to this drug. However, the use of an-
cestry in the drug labeling creates po-
tential safety problems for patients, 
cost concerns for patients and insur-
ers, and potential stigmatization of a 
drug that has been used for years to 
treat complex neurological illnesses. 
Categorizing people for personalized 
medicine must be done, if at all, in a 
scientifically valid, sensitive, and eth-
ical manner.
Perry W. Payne, Jr.
The use of ancestry in the drug labeling creates potential safety problems for 
patients, cost concerns for patients and insurers, and potential stigmatization 
of a drug that has been used for years to treat complex neurological illnesses. 
Categorizing people for personalized medicine must be done, if at all, in a 
scientifically valid, sensitive, and ethical manner.
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